AIM Debt To Assets from 2010 to 2024

AIM Stock  USD 0.23  0.02  9.52%   
AIM ImmunoTech Debt To Assets yearly trend continues to be very stable with very little volatility. Debt To Assets are likely to drop to 0.01. During the period from 2010 to 2024, AIM ImmunoTech Debt To Assets quarterly data regression pattern had sample variance of  0.01 and median of  0.13. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.0132
Current Value
0.0126
Quarterly Volatility
0.1072887
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AIM ImmunoTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AIM ImmunoTech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 226.1 K, Total Revenue of 386.8 K or Gross Profit of 168 K, as well as many indicators such as Price To Sales Ratio of 101, Dividend Yield of 0.0 or PTB Ratio of 1.98. AIM financial statements analysis is a perfect complement when working with AIM ImmunoTech Valuation or Volatility modules.
  
Check out the analysis of AIM ImmunoTech Correlation against competitors.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.

Latest AIM ImmunoTech's Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of AIM ImmunoTech over the last few years. It is AIM ImmunoTech's Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AIM ImmunoTech's overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

AIM Debt To Assets Regression Statistics

Arithmetic Mean0.12
Geometric Mean0.06
Coefficient Of Variation92.85
Mean Deviation0.08
Median0.13
Standard Deviation0.11
Sample Variance0.01
Range0.3743
R-Value(0.59)
Mean Square Error0.01
R-Squared0.35
Significance0.02
Slope(0.01)
Total Sum of Squares0.16

AIM Debt To Assets History

2024 0.0126
2023 0.0132
2020 0.0115
2019 0.2
2018 0.26
2012 0.13
2011 0.0477

About AIM ImmunoTech Financial Statements

AIM ImmunoTech investors utilize fundamental indicators, such as Debt To Assets, to predict how AIM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Debt To Assets 0.01  0.01 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out the analysis of AIM ImmunoTech Correlation against competitors.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.47)
Revenue Per Share
0.004
Quarterly Revenue Growth
0.19
Return On Assets
(0.80)
Return On Equity
(1.55)
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.